People who take popular weight-loss drugs like Ozempic and Mounjaro have reduced their spending at restaurants and on takeout, according to a new survey.
A staggering 63 percent of those who use the drugs, called GLP-1, are spending less at restaurants now than before they started taking the prescription drugs, according to a Morgan Stanley AlphaWise survey released last week.
In addition, 61 percent of 300 American patients taking GLP-1 surveyed by Morgan Stanley are reducing the amount they spend on takeout and delivery, CNBC previously reported.
There is growing evidence that drugs have a significant impact on consumer behavior and spending at restaurants and groceries, Morgan Stanley analysts concluded.
All of these dynamics suggest that the impact of GLP-1 drugs on consumer sectors will increase as drug uptake grows and drugs modify behavior among a demographic that represents a disproportionate share of caloric intake.
An estimated 31.5 million people, or about 9% of the US population, are expected to take GLP-1 by 2035.
GLP-1 drugs, most of which are injections, contain strong drugs that mimic the actions of the hormone GLP-1, which the pancreas releases after eating and which makes people feel full.
Still, Morgan Stanley analysts assured that the change in consumer spending habits will not affect restaurant results too much.
Restaurants offer convenience and/or experience in addition to food, and that won’t change with the use of GLP-1, analysts say, according to CNBC.
Rather, some restaurants may have to tweak their menu to attract more health-conscious customers, they added, noting that healthier chains like Cava, Chipotle, Sweetgreen and Starbucks are better positioned to adapt to the changes. in consumer spending habits.
Meanwhile, more indulgent fast-casual restaurants could face more pressure, including Jack in the Box, Wendys, Wingstop, Shake Shack and Portillos, according to Morgan Stanley.
Snack and beer distributors have already warned that Ozempic and Wegovy, drugs originally created as a diabetes treatment that have since become popular for their appetite-suppressing benefits, have affected consumer behaviors.
Morgan Stanley warned that Hershey is the most risky packaged food company given its large consumer-focused snack portfolio in the US, according to CNBC.
Hershey’s portfolio, for reference, includes candy brands like Reese’s and Kit Kat to savory options like Pirate’s Booty, SkinnyPop Popcorn and Dot’s Homestyle Pretzels.
On the other hand, snack giants such as Vital Farms, whose slogan is “Keeping it Bulls-t-Free”, as well as Bellring Brands, maker of Premier protein drinks, and Simply Good Foods, which makes Quest Nutrition, are ready to benefit from GLP. -1s popularity, said Morgan Stanley.
Last year, Walmart’s U.S. chief John Furner told Bloomberg News that Ozempic was the reason customers were buying fewer units and consuming slightly fewer calories.
We definitely see a slight change compared to the total population, we see a slight pullback in the overall basket, Furner said at the time.
After Furner’s comment, shares of Swiss snack conglomerate Nestlé, the Kraft Heinz Company and Oreo maker Mondelez International were sent tumbling, along with beer giant Constellation Brands, the US distributor of Special Model
#People #weightloss #drugs #Ozempic #save #big #restaurants #takeout #survey
Image Source : nypost.com